CTOs on the Move

Biofire Diagnostics

www.biofiredx.com

 
With more than 25 years of molecular experience, BioFire Diagnostics, LLC sets the standard for molecular diagnostics through its pioneering advances in syndromic infectious disease testing. As BioMérieux`s Global Center of Excellence for Molecular Diagnostics, no other company has FDA-cleared and CE-IVD marked assays for more pathogens. BioFire Diagnostics has produced the easiest, fastest, and most comprehensive multiplex PCR testing available: the BioFire® FilmArray® System.
  • Number of Employees: 1K-5K
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Synertech Inc

Synertech Inc is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gene Scan USA Inc

Gene Scan USA Inc is a Belle Chasse, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medstar Laboratory

Medstar Laboratory, Inc. was funded in 1974 and serviced the Chicago metropolitan area. In February 2001, the Patel family took ownership. Under their administration the company has expanded its client base to Wisconsin and Indiana experiencing an extraordinary growth.

Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce is developing two clinical-stage programs as well as advancing and building out its broad and wholly-owned discovery pipeline of immuno-oncology targets, including those expressed on T-regulatory cells, macrophages and stromal cells. Jounce`s lead product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS and is currently being assessed in a Phase 2 clinical trial. JTX-4014 is a PD-1 inhibitor intended for use in combination with future pipeline products, and Jounce has completed enrollment in the JTX-4014 Phase 1 clinical trial. In addition, Jounce has exclusively licensed worldwide rights to JTX-8064, a LILRB2 receptor antagonist, to Celgene. For more information, please visit www.jouncetx.com. We have many career opportunities at Jounce and are looking for exceptional individuals who share our passion and perseverance for developing highly durable cancer immunotherapies that can dramatically impact and improve patients` lives.

Spokane Allergy and Asthma

Spokane Allergy and Asthma is a Spokane, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.